An EUA for casirivimab and imdevimab for COVID-19

Med Lett Drugs Ther. 2020 Dec 28;62(1614):201-202.
No abstract available

Keywords: COVID-19; adverse effects; casirivimab; coronavirus; dosage; efficacy; imdevimab; safety.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • COVID-19 Drug Treatment*
  • Child
  • Drug Approval
  • Female
  • Humans
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • United States
  • United States Food and Drug Administration
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • imdevimab
  • casirivimab